Once-weekly exenatide vs once- or twice-daily insulin detemir: randomised, open-label clinical trial of efficacy and safety in patients with Type 2 diabetes inadequately controlled with metformin alone or with sulphonylureas

被引：0
|
作者：
Davies, M. [1 ]
Heller, S. [2 ]
Sreenan, S. [3 ]
Sapin, H. [4 ]
Adetunji, O. [5 ]
Tahbaz, A. [5 ]
Vora, J. [6 ]
机构：
[1] Univ Leicester, Leicester, Leics, England
[2] Univ Sheffield, Acad Unit Diabet Endocrinol & Metab, Sheffield, S Yorkshire, England
[3] Connolly Hosp, Royal Coll Surg Ireland, Dublin, Ireland
[4] Lilly France, Suresnes, France
[5] Eli Lilly & Co, Basingstoke, Hants, England
[6] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England
来源：
DIABETIC MEDICINE | 2013年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：57 / 58
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of once- and twice-daily formulations of molsidomine in patients with stable angina pectoris:: Double-blind and open-label studies
    Messin, R
    Carreer-Bruhwyler, F
    Dubois, C
    Famaey, JP
    Géczy, J
    ADVANCES IN THERAPY, 2006, 23 (01) : 107 - 130
  • [22] Efficacy and Safety of Once-Weekly Somapacitan in Childhood Growth Hormone Deficiency: Results of a Randomised Open-Label, Controlled Phase 2 Trial
    Savendal, Lars
    Rasmussen, Michael
    Horikawa, Reiko
    Khadilkar, Vaman
    Battelino, Tadej
    Saenger, Paul
    HORMONE RESEARCH IN PAEDIATRICS, 2018, 90 : 58 - 58
  • [23] Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
    Ahmann, Andrew J.
    Capehorn, Matthew
    Charpentier, Guillaume
    Dotta, Francesco
    Henkel, Elena
    Lingvay, Ildiko
    Holst, Anders G.
    Annett, Miriam P.
    Aroda, Vanita R.
    DIABETES CARE, 2018, 41 (02) : 258 - 266
  • [24] DURATION-8 randomised controlled trial 1-year results: efficacy and safety of once-weekly exenatide plus once-daily dapagliflozin versus exenatide or dapagliflozin alone
    Guja, C.
    Frias, J. P.
    Ahmed, A. A.
    Hardy, E.
    Wang, H.
    Ohman, P.
    Jabbour, S. A.
    DIABETOLOGIA, 2017, 60 : S5 - S5
  • [25] A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy
    Shankar, R. Ravi
    Inzucchi, Silvio E.
    Scarabello, Victoria
    Gantz, Ira
    Kaufman, Keith D.
    Lai, Eseng
    Ceesay, Paulette
    Suryawanshi, Shailaja
    Engel, Samuel S.
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (10) : 1853 - 1860
  • [26] Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study
    Buse, J. B.
    Nauck, M. A.
    Forst, T.
    Sheu, W. H. H.
    Hoogwerf, B. J.
    Shenouda, S. K.
    Heilmann, C. R.
    Boardman, M. K.
    Fineman, M.
    Porter, L.
    Schernthaner, G.
    DIABETOLOGIA, 2011, 54 : S38 - S38
  • [27] Initiation of insulin glargine in patients with Type 2 diabetes suboptimally controlled on once- or twice-daily NPH insulin: results from the AT.LANTUS trial
    Fulcher, GR
    Storms, F
    Shutler, S
    Leperlier, C
    Gomis, R
    Davies, M
    DIABETOLOGIA, 2004, 47 : A272 - A272
  • [28] Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
    Frias, Juan P.
    Guja, Cristian
    Hardy, Elise
    Ahmed, Azazuddin
    Dong, Fang
    Ohman, Peter
    Jabbour, Serge A.
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (12): : 1004 - 1016
  • [29] Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study
    Frias, Juan
    Chien, Jenny
    Zhang, Qianyi
    Chigutsa, Emmanuel
    Landschulz, William
    Syring, Kristen
    Wullenweber, Paula
    Haupt, Axel
    Kazda, Christof
    LANCET DIABETES & ENDOCRINOLOGY, 2023, 11 (03): : 158 - 168
  • [30] Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial
    Ross, S.
    Thamer, C.
    Cescutti, J.
    Meinicke, T.
    Woerle, H. J.
    Broedl, U. C.
    DIABETES OBESITY & METABOLISM, 2015, 17 (07): : 699 - 702
12345